Tumor-associated antigens as possible targets for immune therapy in head and neck cancer

• Verfasst von: Götte, Karl [VerfasserIn]
• Verfasst von: Riedel, Frank [VerfasserIn]
• Verfasst von: Hörmann, Karl [VerfasserIn]
• Verfasst von: Schadendorf, Dirk [VerfasserIn]
• Verfasst von: Eichmüller, Stefan B. [VerfasserIn]
• Titel: Tumor-associated antigens as possible targets for immune therapy in head and neck cancer
• Titelzusatz: comparative mRNA expression analysis of RAGE and GAGE genes
• Verf.angabe: Karl Götte, Dirk Usener, Frank Riedel, Karl Hörmann, Dirk Schadendorf and Stefan Eichmüller
• Jahr: 2002
• Umfang: 7 S.
• Fussnoten: Elektronische Reproduktion der Druckausgabe ; Gesehen am 17.11.2020
• Titel Quelle: Enthalten in: Acta oto-laryngologica
• Ort Quelle: Stockholm : Taylor & Francis Group, 1918
• Jahr Quelle: 2002
• Band/Heft Quelle: 122(2002), 5, Seite 546-552
• ISSN Quelle: 1651-2251
• DOI: doi:10.1080/00016480260092381
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Antigens
• Sach-SW: Associated
• Sach-SW: Cancer
• Sach-SW: Gage
• Sach-SW: Head
• Sach-SW: Immune
• Sach-SW: Neck
• Sach-SW: Rage
• Sach-SW: Specific
• Sach-SW: Therapy
• Sach-SW: Tumor
• K10plus-PPN: 1738930777

Abstract

Specific immune therapy targeting residual areas of cancer cells may emerge as a powerful treatment strategy for head and neck squamous cell carcinoma (HNSCC). In order to define possible targets for immune therapy, we evaluated the frequency of two groups of tumor antigens - the RAGE and GAGE families - by means of reverse transcriptase polymerase chain reaction using primary HNSCCs ( n =28), mucosa specimens as normal controls ( n =10) and HNSCC cell lines ( n =6). By means of specific primer selection we could differentiate between RAGE-1, -2, -3 and-4, as well as between two groups of GAGE genes (GAGE-1,2,7 vs GAGE-3,4,5,6,8). While all mucosa tissues (from smokers and non-smokers) were negative for both antigen families, 24/28 investigated tumors were positive for up to 5 tumor antigens. Among the RAGE genes, RAGE-1-positive tumors were the most abundant (8/28), followed by RAGE-2 (7/28) and RAGE-4 (6/28). Differences in the locations of HNSCCs were reflected by different RAGE family members being expressed most frequently: larynx, RAGE-1; oropharynx, RAGE-2; and hypopharynx, RAGE-4. Primers against GAGE-1,2,7 and GAGE-3,4,5,6,8 revealed 6/27 and 16/27 positive tumors, respectively. This report suggests that RAGE genes and GAGE-3,4,5,6,8 may be promising candidates for specific immune therapy in HNSCC.